NO315271B1 - 4-brom- eller 4-jod-fenylamino-benzhydroksamsyrederivater, anvendelse deravog farmasöytiske preparater inneholdende dem - Google Patents

4-brom- eller 4-jod-fenylamino-benzhydroksamsyrederivater, anvendelse deravog farmasöytiske preparater inneholdende dem Download PDF

Info

Publication number
NO315271B1
NO315271B1 NO19996491A NO996491A NO315271B1 NO 315271 B1 NO315271 B1 NO 315271B1 NO 19996491 A NO19996491 A NO 19996491A NO 996491 A NO996491 A NO 996491A NO 315271 B1 NO315271 B1 NO 315271B1
Authority
NO
Norway
Prior art keywords
benzamide
difluoro
iodo
bromo
methylphenylamino
Prior art date
Application number
NO19996491A
Other languages
English (en)
Norwegian (no)
Other versions
NO996491D0 (no
NO996491L (no
Inventor
Stephen Douglas Barrett
Alexander James Bridges
Annette Marian Doherty
David Thomas Dudley
Alan Robert Saltiel
Haile Tecle
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO996491D0 publication Critical patent/NO996491D0/no
Publication of NO996491L publication Critical patent/NO996491L/no
Publication of NO315271B1 publication Critical patent/NO315271B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19996491A 1997-07-01 1999-12-27 4-brom- eller 4-jod-fenylamino-benzhydroksamsyrederivater, anvendelse deravog farmasöytiske preparater inneholdende dem NO315271B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5144097P 1997-07-01 1997-07-01
PCT/US1998/013106 WO1999001426A1 (fr) 1997-07-01 1998-06-24 Derives d'acide benzhydroxamique phenylamino 4-bromo ou 4-iodo et utilisation de ces derniers en tant qu'inhibiteurs de mek

Publications (3)

Publication Number Publication Date
NO996491D0 NO996491D0 (no) 1999-12-27
NO996491L NO996491L (no) 1999-12-29
NO315271B1 true NO315271B1 (no) 2003-08-11

Family

ID=21971339

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19996491A NO315271B1 (no) 1997-07-01 1999-12-27 4-brom- eller 4-jod-fenylamino-benzhydroksamsyrederivater, anvendelse deravog farmasöytiske preparater inneholdende dem

Country Status (26)

Country Link
EP (1) EP0993439B1 (fr)
JP (1) JP2002511092A (fr)
KR (1) KR20010014362A (fr)
CN (1) CN1163475C (fr)
AR (1) AR016762A1 (fr)
AT (1) ATE277895T1 (fr)
AU (1) AU757046B2 (fr)
BR (1) BR9810366A (fr)
CA (1) CA2290506C (fr)
CO (1) CO4940442A1 (fr)
DE (1) DE69826662T2 (fr)
ES (1) ES2229515T3 (fr)
HR (1) HRP980368A2 (fr)
HU (1) HUP0003731A3 (fr)
IL (1) IL132840A (fr)
IS (1) IS5256A (fr)
MY (1) MY120994A (fr)
NO (1) NO315271B1 (fr)
NZ (1) NZ501276A (fr)
PE (1) PE97999A1 (fr)
PL (1) PL337698A1 (fr)
PT (1) PT993439E (fr)
TW (1) TW396149B (fr)
UY (1) UY25076A1 (fr)
WO (1) WO1999001426A1 (fr)
ZA (1) ZA985728B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106298A1 (fr) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Mutations de braf conférant une résistance aux inhibiteurs de braf
WO2013169858A1 (fr) 2012-05-08 2013-11-14 The Broad Institute, Inc. Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
TR200101704T2 (tr) * 1998-12-15 2001-11-21 Warner-Lambert Company Transplant reddinin engellenmesi için bir MEK inhibitörünün kullanımı
WO2000040237A1 (fr) * 1999-01-07 2000-07-13 Warner-Lambert Company Methode antivirale utilisant des inhibiteurs de mek
CA2348236A1 (fr) * 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, et 4-arylthio diarylamines et leurs derives comme inhibiteurs selectifs de mek
WO2000042003A1 (fr) 1999-01-13 2000-07-20 Warner-Lambert Company Derives de benzenesulfonamide et leur utilisation comme inhibiteurs de mek
KR20010108093A (ko) 1999-01-13 2001-12-07 로즈 암스트롱, 크리스틴 에이. 트러트웨인 1-헤테로고리 치환된 디아릴아민
CA2355470C (fr) 1999-01-13 2008-09-30 Warner-Lambert Company Les benzoheterocycles et leur utilisation comme inhibiteurs de mek
AU2482800A (en) 1999-01-13 2000-08-01 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
ATE286015T1 (de) * 1999-04-21 2005-01-15 Warner Lambert Co Verfahren zur herstellung von 2-(n- phenylalmino)benzoesäure
US6686499B1 (en) 1999-04-21 2004-02-03 Warner-Lambert Company Method for making 2-(N-phenylamino)benzoic acids
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
CA2374052A1 (fr) * 1999-07-16 2001-01-25 Warner-Lambert Company Traitement des douleurs chroniques par des inhibiteurs de mek
JP2003527379A (ja) * 2000-03-15 2003-09-16 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類
US7001905B2 (en) 2000-03-15 2006-02-21 Warner-Lambert Company Substituted diarylamines as MEK inhibitors
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
BR0113520A (pt) * 2000-08-25 2003-06-24 Warner Lambert Co Processo de preparação de ácidos n-aril-antranìlicos e seus derivados
CA2419567A1 (fr) 2000-09-01 2002-03-07 George Vande Woude Inhibition de la voie de la proteine mapkkk: une strategie therapeutique selective contre les melanomes
WO2002036570A1 (fr) 2000-11-02 2002-05-10 Astrazeneca Ab Quinoleines 4 substitues en position 4 utilisees comme agents antitumoraux
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
EP1377312A4 (fr) * 2001-03-22 2004-10-06 Andel Inst Van Facteur letal de l'anthrax inhibant la croissance tumorale et l'angiogenese
IL149462A0 (en) * 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2003062191A1 (fr) * 2002-01-23 2003-07-31 Warner-Lambert Company Llc Esters hydroxamates d'acide n-(phenyl substitue en 4)-anthranilique
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
ES2407849T3 (es) 2002-03-13 2013-06-14 Array Biopharma, Inc. Derivados de bencimidazol alquilados N3 como inhibidores de MEK
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2005009975A2 (fr) 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazoles n-methyle-substitues
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
WO2005028426A1 (fr) 2003-09-19 2005-03-31 Chugai Seiyaku Kabushiki Kaisha Nouveau derive de 4-phenylamino-benzaldoxime et son utilisation en tant qu'inhibiteur de mek
RU2352558C2 (ru) 2003-10-21 2009-04-20 Уорнер-Ламберт Компани Ллс Полиморфная форма n-[(r)-2,3-дигидроксипропокси]-3,4-дифтор-2-(2-фтор-4 йодфениламино)бензамида
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
DE602004031037D1 (de) 2003-11-19 2011-02-24 Array Biopharma Inc Heterocyclische inhibitoren von mek
CN102786482A (zh) 2003-11-21 2012-11-21 阿雷生物药品公司 Akt蛋白激酶抑制剂
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
BRPI0509580A (pt) * 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
KR100889721B1 (ko) 2004-08-17 2009-03-23 에프. 호프만-라 로슈 아게 치환 히단토인
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
EA013212B1 (ru) 2004-10-20 2010-04-30 Лаборатуар Сероно Са 3-ариламинопиридиновые производные
US8022247B2 (en) 2005-04-06 2011-09-20 Chugai Seiyaku Kabushiki Kaisha Process for production of 2,3,4-trifluoro-5-(iodo or bromo)-benzoic acid
MY149960A (en) 2005-05-18 2013-11-15 Array Biopharma Inc 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
CA2927656C (fr) 2005-10-07 2019-09-24 Exelixis, Inc. Azetidines en tant qu'inhibiteurs de mek
US7612212B2 (en) 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins
JPWO2007132867A1 (ja) 2006-05-15 2009-09-24 杉本　芳一 癌の予防及び治療剤
DE602007011628D1 (de) 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2054418B1 (fr) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothiéno pyrimidines comme inhibiteurs de la protéine kinase akt
RU2481336C2 (ru) 2006-07-06 2013-05-10 Эррэй Биофарма Инк. Циклопента(d)пиримидины в качестве ингибиторов протеинкиназ акт
EP1908751A1 (fr) * 2006-10-03 2008-04-09 EOS S.p.A. Dérivés de N-hydroxybenzamide ayant une activité antitumorale
CN101563338A (zh) 2006-10-23 2009-10-21 武田药品工业株式会社 Mapk/erk激酶抑制剂
CA2671982C (fr) 2006-12-14 2016-01-26 Exelixis, Inc. Procedes d'utilisation d'inhibiteurs de mek
JPWO2008075741A1 (ja) * 2006-12-20 2010-04-15 国立大学法人 長崎大学 糖尿病治療剤及び予防剤
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
KR20150091196A (ko) 2007-07-05 2015-08-07 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
ES2383927T3 (es) 2007-08-16 2012-06-27 F. Hoffmann-La Roche Ag Hidantoínas sustituidas
EP2234982A1 (fr) 2007-12-20 2010-10-06 F. Hoffmann-La Roche AG Hydantoïnes substituées en tant qu'inhibiteurs de la mek kinase
JP5539225B2 (ja) 2008-01-09 2014-07-02 アレイ バイオファーマ、インコーポレイテッド Ａｋｔタンパク質キナーゼ阻害剤としての水酸化されたピリミジルシクロペンタン
WO2009089459A1 (fr) 2008-01-09 2009-07-16 Array Biopharma Inc. Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
WO2009143224A2 (fr) 2008-05-20 2009-11-26 Fox Chase Center Center Procédé de traitement ou de prophylaxie d'une lymphangioléiomyomatose (lam) et modèle animal pour une utilisation dans la recherche sur la lam
MX2011001127A (es) 2008-08-04 2011-03-21 Merck Patent Gmbh Compuestos novedosos de fenilamino-isonicotinamida.
WO2010022725A1 (fr) 2008-08-27 2010-03-04 Leo Pharma A/S Dérivés de pyridine comme récepteur de vegfr-2 et inhibiteurs de la protéine tyrosine kinase
CA2742945A1 (fr) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Sulfonamido phenoxybenzamides substitues
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
CN102574782B (zh) 2009-10-21 2014-10-08 拜耳知识产权有限责任公司 取代的卤代苯氧基苯甲酰胺衍生物
EP2491015A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitués
EP2491016A1 (fr) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Benzosulfonamides substitués
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
US9045429B2 (en) 2010-10-29 2015-06-02 Bayer Intellectual Property Gmbh Substituted phenoxypyridines
AU2011349446C1 (en) 2010-12-22 2016-01-21 Fate Therapauetics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
MX2013011333A (es) 2011-04-01 2014-04-16 Genentech Inc Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
EP2694072B1 (fr) 2011-04-01 2017-11-29 Genentech, Inc. Combinaison de composé inhibiteur d'akt et d'abiraterone pour utilisation dans des traitements thérapeutiques
CA2836364C (fr) 2011-05-25 2021-01-26 Universite Paris Descartes Inhibiteurs de la voie erk pour le traitement de l'amyotrophie spinale
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
MX2015004660A (es) 2012-10-12 2015-08-07 Exelixis Inc Proceso novedoso para la elaboración de compuestos para su uso en el tratamiento del cáncer.
WO2015038704A1 (fr) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions pour prépaprer des cardiomyocytes
EP3805369A1 (fr) 2014-03-04 2021-04-14 Fate Therapeutics, Inc. Procédés améliorés de reprogrammation et plateformes de culture cellulaire
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
AU2016211671B2 (en) 2015-01-26 2022-05-26 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
CA3003150A1 (fr) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Ingenierie genomique de cellules pluripotentes
CN108473961B (zh) 2015-11-04 2022-11-29 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
EP3405568A4 (fr) 2016-01-20 2019-12-04 Fate Therapeutics, Inc. Compositions et procédés de modulation des cellules immunitaires en immunothérapies adoptives
KR20180096707A (ko) 2016-01-20 2018-08-29 페이트 세러퓨틱스, 인코포레이티드 입양 면역요법에서 면역 세포 조절을 위한 조성물 및 방법
JP7194436B2 (ja) * 2016-07-28 2022-12-22 ザ ジョンズ ホプキンス ユニバーシティ Ｏ－置換ヒドロキサム酸
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
CN107556201B (zh) * 2017-09-08 2020-10-27 山西智创药研科技有限公司 一种制备间氨基苯酚的工艺方法
WO2020106303A1 (fr) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
CA3120352A1 (fr) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composes thienyl-aniline destines au traitement d'affections de la peau
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011106298A1 (fr) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Mutations de braf conférant une résistance aux inhibiteurs de braf
WO2013169858A1 (fr) 2012-05-08 2013-11-14 The Broad Institute, Inc. Méthodes de diagnostic et de traitement chez des patients ayant ou présentant un risque de développer une résistance à une thérapie anticancéreuse

Also Published As

Publication number Publication date
AU8262798A (en) 1999-01-25
CO4940442A1 (es) 2000-07-24
NO996491D0 (no) 1999-12-27
CA2290506C (fr) 2005-12-27
AU757046B2 (en) 2003-01-30
DE69826662D1 (de) 2004-11-04
AR016762A1 (es) 2001-08-01
HUP0003731A2 (hu) 2001-04-28
IL132840A (en) 2004-12-15
EP0993439A1 (fr) 2000-04-19
ES2229515T3 (es) 2005-04-16
KR20010014362A (ko) 2001-02-26
HUP0003731A3 (en) 2002-11-28
BR9810366A (pt) 2000-08-29
PL337698A1 (en) 2000-08-28
WO1999001426A1 (fr) 1999-01-14
NZ501276A (en) 2000-10-27
DE69826662T2 (de) 2005-02-17
ZA985728B (en) 1999-01-27
CN1261877A (zh) 2000-08-02
JP2002511092A (ja) 2002-04-09
ATE277895T1 (de) 2004-10-15
HRP980368A2 (en) 1999-04-30
NO996491L (no) 1999-12-29
EP0993439B1 (fr) 2004-09-29
TW396149B (en) 2000-07-01
IL132840A0 (en) 2001-03-19
PE97999A1 (es) 1999-11-05
CN1163475C (zh) 2004-08-25
UY25076A1 (es) 1998-12-01
CA2290506A1 (fr) 1999-01-14
PT993439E (pt) 2004-12-31
IS5256A (is) 1999-11-19
MY120994A (en) 2005-12-30

Similar Documents

Publication Publication Date Title
NO315271B1 (no) 4-brom- eller 4-jod-fenylamino-benzhydroksamsyrederivater, anvendelse deravog farmasöytiske preparater inneholdende dem
US7169816B2 (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
DE69836378T2 (de) Benzoesäure- und Benzamid-Derivate von Anthranilsäure und ihre Anwendung als MEK-Inhibitoren
US7019033B2 (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives
US20210053915A1 (en) N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
AU2008315651B2 (en) Histone deacetylase inhibitors
CA2628863A1 (fr) Composition et synthese de nouveaux reactifs pour inhiber la replication du vih
EP1519932A1 (fr) Composes de bisarylsulfonamide et leur utilisation dans le traitement du cancer
SK8712001A3 (en) Combination chemotherapy
WO2022107745A1 (fr) Agent thérapeutique ou agent prophylactique contre la covid-19
KR20200131249A (ko) 항-염증제, 면역조절제 및 항-증식제로서의 신규한 칼슘 염 다형체
Zhou et al. Structures and physicochemical properties of vortioxetine salts
Imran et al. Development, molecular docking, and in silico ADME evaluation of selective ALR2 inhibitors for the treatment of diabetic complications via suppression of the polyol pathway
CN110139854A (zh) O-取代异羟肟酸
MXPA99010649A (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
CN106883214B (zh) 一种Aβ寡聚化抑制剂、合成方法及应用
WO2024044553A1 (fr) Utilisation de (isoindolin-2-yl)(4-hydroxy-3-(isoindoline-2-carbonyl)phényl)méthanones dans le traitement du dysfonctionnement de la protéine 1 associée au récepteur du facteur de nécrose tumorale
MXPA99010556A (en) 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
NO149546B (no) Analogifremgangsmaate for fremstilling av et nytt, terapeutisk aktivt aminoalkylfuran-derivat

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees